Pluristem, U.S. DoD to announce data from studies testing PLX-R18
Pluristem Therapeutics announced that results from a series of studies of the company's PLX-R18 cell therapy product conducted by the U.S. Department of Defense's Armed Forces Radiobiology Research Institute at the Uniformed Services University of the Health Sciences, will be jointly presented at the upcoming 2019 Radiation Injury Treatment Network Workshop on July 31st. The animal studies, conducted following guidance from the U.S. Food and Drug Administration relating to its animal rule pathway, are designed to evaluate PLX-R18 as a potential prophylactic countermeasure against acute radiation syndrome administered prior to radiation exposure. In addition to the DoD study, PLX-R18 is also being evaluated by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, as a treatment following radiation exposure. Data from these studies demonstrated a significant increase in survival rates and enhanced neutrophil and lymphocyte recovery in radiation subjects. The company's PLX-R18 cell therapy product was granted an FDA orphan drug designation and an IND for the treatment of ARS.